Clinilabs adds ECG to offering with NewCardio deal

By Staff Reporter

- Last updated on GMT

Related tags: Clinical trial

US CRO Clinilabs has licensed NewCardio’s QTinno cardiac safety analysis software, adding ECG services to it drug industry offering.

The technology, which enables fully-automated cardiac safety analyses in cardiac intensive and QT studies, will be used at the contract research organisation’s (CRO) dedicated clinical research unit in Manhatten, New York.

The deal, financial terms of which were not disclosed, also includes a services agreement that will see NewCardio participate in the development of a new on-site electrocardiogram (ECG) analysis laboratory.

Clinilabs’ CEO, Gary Zammit, said: “We can now provide a differentiated and low cost solution for ECG data analysis to an industry that has been seeking a meaningful alternative to existing methods for some time​.”

Vincent Renz, NewCardio’s COO was also upbeat about the partnership, explaining that it “is further evidence of the growing adoption of QTinno by innovative clinical trial service providers.”

Our target customers are clinical trial service providers looking to deploy our proven technology to expand services and grow market opportunities. For Clinilabs, adding to its available scope of services by utilizing QTinno accomplished these two important goals​.”

ECG solutions

California-headquartered NewCardio, which has previously​ said its QTinno software is being used by a “Top 5 CRO,” expects growing regulatory pressure for early safety analysis will drive further demand for its technologies.

The firm explained that: “Screening for the risk of drug-induced adverse, often lethal, cardiovascular events – such as those identified with Vioxx, Seldane, and Avandia is of utmost importance for drug developers, and the public health in general.”

This, NewCardio went on to explain, can pose a problem for traditional ECG analysis during development which, for some studies, can involve the analysis of multiple ECG time points from one thousand or more patients.

Using NewCardio’s 3-D approach, drug sponsors and CROs can automate this process, significantly reducing the cost and variability compared with non-automated methods, and reducing the time required to test new drugs in development​.”

Related news

Show more

Related products

show more

Paper vs ePRO Data Collection Methods

Paper vs ePRO Data Collection Methods

Signant Health | 19-Oct-2021 | Technical / White Paper

Are you curious why more Sponsors choose digital data collection methods over the traditional pen and paper? Read this recent white paper to discover the...

GLP Tissue Cross Reactivity Testing

GLP Tissue Cross Reactivity Testing

Precision for Medicine | 11-Oct-2021 | Product Brochure

Precision for Medicine's unique combination of research services and tissue procurement capabilities form the pillars of our GLP Tissue Cross Reactivity...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Related suppliers

Follow us


View more